- PharmAla Biotech Holdings Inc. launched **NEXUS**, a new tool to connect prescribers, therapists, and clinic managers for MDMA practitioners, aiming to improve care delivery and knowledge sharing.  **[1157075_2d3d2728bf1f4dcd947903d875d991a5_0]** 
- The company announced the appointment of **Farnoud Kazemzadeh** as its new **Chief Operating Officer**.  **[1157075_2d3d2728bf1f4dcd947903d875d991a5_0]** 
- **Dr. Harriet De Wit** resigned from PharmAla's board of directors.  **[1157075_2d3d2728bf1f4dcd947903d875d991a5_0]**

PharmAla Launches NEXUS Portal and Announces Management Changes

- PharmaCyte Biotech, Inc. (PMCB) has increased its stake in TNF Pharmaceuticals (TNFA) by an additional **$3 million**.  **[1157075_7640e80c1caf47f88a7d1257eb29f746_0]** 
- This investment supports TNF's recent license acquisition from LightSolver, Ltd., for a **revolutionary processing accelerator** that uses light for computation.  **[1157075_7640e80c1caf47f88a7d1257eb29f746_0]** 
- The LightSolver technology is designed to **reduce energy output by 90%** and offers greater speed and efficiency than conventional computing methods, with applications in **cryptocurrency mining and blockchain**.  **[1157075_7640e80c1caf47f88a7d1257eb29f746_0]** 
- TNF Pharmaceuticals is expected to **change its name and ticker symbol** to align with its new strategic focus.  **[1157075_7640e80c1caf47f88a7d1257eb29f746_0]** 
- As of **April 30, 2025**, PharmaCyte Biotech remains well-capitalized with **over $55 million** in total assets.  **[1157075_7640e80c1caf47f88a7d1257eb29f746_0]**

PharmaCyte Biotech (PMCB)